Form 4: Aptevo Therapeutics Director Converts Restricted Stock Units to Common Shares

Aptevo Therapeutics Inc. Director Zsolt Harsanyi is set to convert a restricted stock unit into one common share on July 17, 2025, following a significant stock split.

Summary

• Zsolt Harsanyi, a Director of Aptevo Therapeutics Inc. (APVO), will acquire 1 share of common stock through the conversion of a Restricted Stock Unit (RSU) on July 17, 2025.
• The RSU converts into common stock on a one-for-one basis.
• The RSU was granted on July 17, 2024, and vests in full one year from the grant date.
• The original grant was for 925 RSUs, which became 1 RSU post-stock splits, indicating a substantial reverse stock split by the company.

Sentiment

Score: 3

Explanation: The conversion of a single RSU into common stock, while an increase in direct ownership, is overshadowed by the implied massive reverse stock split (925 pre-split RSUs to 1 post-split share), which is typically a negative indicator of a company's financial health or market standing.

Positives

• A Director is increasing their direct beneficial ownership in the company, albeit by a small amount, which can signal alignment with shareholder interests.

Negatives

• The conversion of only 1 share, which originated from 925 pre-split RSUs, strongly implies a very significant reverse stock split, often a negative indicator of a company's financial health or stock performance.
• The extremely high ratio of the implied reverse stock split (925 pre-split RSUs to 1 post-split share) suggests severe dilution or a very low share price prior to the split.

Risks

• The company likely underwent a substantial reverse stock split, which can be a sign of financial distress, an attempt to maintain listing compliance, or to improve stock perception, but often leads to further share price volatility and investor concern.
• A reverse stock split of this magnitude may indicate underlying operational or financial challenges that could impact future share value.

Future Outlook

The document indicates a future scheduled event where a Restricted Stock Unit will convert into one common share on July 17, 2025, as part of a pre-existing grant agreement.

Industry Context

This Form 4 filing is a routine disclosure of an insider's change in beneficial ownership. While the transaction itself is small, the implied reverse stock split context is more significant, as such actions are common in the biotechnology sector for companies facing low stock prices or seeking to meet exchange listing requirements.

Comparison to Industry Standards

• N/A This Form 4 filing does not provide sufficient information for a detailed comparison to industry standards regarding financial performance or operational metrics. It primarily reports an insider stock transaction.

Stakeholder Impact

• Shareholders: The implied reverse stock split could negatively impact existing shareholders by reducing the number of shares they hold, although the value per share should theoretically increase proportionally. However, reverse splits are often viewed negatively by the market.
• Employees: The RSU grant and vesting process is a standard part of employee and director compensation, but the significant stock split could affect the perceived value of equity compensation.

Next Steps

• The actual conversion of the Restricted Stock Unit into one common share is scheduled to occur on July 17, 2025.

Key Dates

Keywords

Aptevo Therapeutics, APVO, Form 4, Insider Transaction, Stock Ownership, Restricted Stock Unit, RSU, Director, Zsolt Harsanyi, Stock Split, Corporate Governance